The issue of financial conflicts of interest in biomedical research and scientific publishing has been a thorny one with which JAMA, the Archives, and academic medicine have wrestled for nearly 2 decades.1-3 Pharmaceutical, biotech, and, increasingly, medical device companies make major investments in sponsoring research in medical schools and pay for consultations with basic scientists and clinical investigators from academic medicine because of the expertise that they can bring to bear on therapeutic innovation. Many of the advances in the treatment of cancer, heart disease, and infectious disease are the fruits of these highly productive relationships. However, financial relationships between medical faculty and industry may not be obvious, unlike the identification of an individual as an employee of a particular company. Such financial relationships include participation in industry-sponsored clinical trials, membership on scientific advisory boards, stock or stock option ownership, consulting, and participation in “speaker bureaus.”
Coyle JT, Heckers S. Update on the Conflict of Interest Policy for the Archives. Arch Gen Psychiatry. 2006;63(11):1178. doi:10.1001/archpsyc.63.11.1178
Psychiatry in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.